Free Trial
NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Verrica Pharmaceuticals logo
$0.69 +0.04 (+6.12%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$0.65 -0.04 (-5.52%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Key Stats

Today's Range
$0.65
$0.72
50-Day Range
$0.41
$0.69
52-Week Range
$0.38
$8.98
Volume
484,602 shs
Average Volume
617,068 shs
Market Capitalization
$63.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Verrica Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

VRCA MarketRank™: 

Verrica Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 266th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Verrica Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verrica Pharmaceuticals is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verrica Pharmaceuticals is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Verrica Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.98% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Verrica Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Verrica Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.98% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for VRCA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verrica Pharmaceuticals' insider trading history.
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

VRCA Stock Analysis - Frequently Asked Questions

Verrica Pharmaceuticals' stock was trading at $0.70 at the beginning of the year. Since then, VRCA stock has decreased by 1.7% and is now trading at $0.6880.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) posted its earnings results on Tuesday, May, 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04. The firm had revenue of $3.44 million for the quarter, compared to analysts' expectations of $2.53 million.
Read the conference call transcript
.

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE).

Company Calendar

Last Earnings
5/13/2025
Today
7/06/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,062.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.58 million
Pretax Margin
-919.21%

Debt

Sales & Book Value

Annual Sales
$7.57 million
Price / Cash Flow
N/A
Book Value
($0.11) per share
Price / Book
-6.25

Miscellaneous

Free Float
42,546,000
Market Cap
$63.63 million
Optionable
Optionable
Beta
1.76
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:VRCA) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners